GW0742: PPARβ/δ Agonist Research Guide

Buy GW0742 Capsules at Loti Labs

In the realm of metabolic research, few compounds have garnered as much scientific attention as GW0742. This research chemical, also known as GW610742 and fitorine, represents a breakthrough in understanding peroxisome proliferator activated receptor β δ (PPARβ/δ) modulation. As part of a class of selective small molecule agonists, GW0742 is widely used to study specific receptor activation and metabolic regulation. Originally developed by GlaxoSmithKline, GW0742 has become an invaluable tool for researchers investigating lipid metabolism, energy homeostasis, and in laboratory settings.

Research suggests that this selective small molecule agonist offers unprecedented insights into nuclear receptor biology, making it a cornerstone compound for metabolic research applications. As scientists continue to explore its mechanisms and applications, GW0742 remains strictly designated for research use only, providing researchers with a powerful tool to advance our understanding of metabolic diseases and vascular biology.

What is GW0742?

GW0742 functions as a potent and highly selective peroxisome proliferator activated receptor β δ agonist, demonstrating remarkable specificity for this particular nuclear receptor. Research indicates that this compound exhibits an EC50 of approximately 1-1.1 nM for PPARβ/δ, showing over 1000-fold selectivity compared to the closely related PPARα and PPARγ isoforms.

The compound’s molecular structure consists of a complex arrangement with the molecular formula C21H17F4NO3S2 and a molecular weight of approximately 471.48 g/mol. Its IUPAC name is 2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-ylmethylthio]-2-methylphenoxyacetic acid, reflecting its sophisticated chemical architecture.

Property	Value
Molecular Weight	471.48 g/mol
EC50 for PPARβ/δ	1-1.1 nM
Selectivity	>1000-fold vs PPARα/γ
Water Solubility	Insoluble
DMSO Solubility	Up to 86 mg/mL

As a research chemical, GW0742 is typically available at high purity (>98-99% by HPLC) and requires specific handling protocols. The compound is insoluble in water but can be dissolved in DMSO or ethanol for experimental applications, making it suitable for various in vitro and in vivo research protocols.

Mechanism of Action of Peroxisome Proliferator Activated Receptor

The biological activity of this selective agonist extends to the upregulation of key enzymes involved in mitochondrial function, including CPT1A (carnitine palmitoyltransferase 1A) and CACT (carnitine/acylcarnitine translocase).

This finding suggests that the compound’s mechanisms involve complex interactions with cellular cofactors and metabolic networks.

• Mitochondrial biogenesis

Studies have revealed that GW0742 can exhibit mixed agonist/antagonist behavior at varied concentrations and shows weak off-target activity on other nuclear receptors, including antagonistic effects at the androgen receptor and vitamin D receptor.

These findings indicate significant potential for studying metabolic regulation in laboratory settings.

Research suggests that these improvements in insulin sensitivity occur through enhanced in skeletal muscle tissue, where the compound upregulates GLUT4 expression.

Key metabolic research applications include:

• Obesity Studies: Diet induced obesity models using C57BL/6 mice
• Diabetes Research: Streptozotocin-induced type 1 diabetes models
• Liver Function: High-fat diet-induced hepatic dysfunction models

In cell culture studies using human umbilical vein endothelial cells (HUVECs), research has shown that GW0742 stimulates angiogenesis and tubulogenesis, particularly when SIRT1 activity is present. These findings suggest applications in studying:

• Angiogenesis mechanisms
• Affecting vascular remodeling pathways

Effects on Diabetic Models

Research Applications and Studies

GW0742 has been extensively utilized in fundamental and translational research, particularly in C57BL/6 mouse models for obesity and diabetes studies. Research protocols commonly employ this compound in hyperinsulinemic-euglycemic clamp studies to assess insulin sensitivity and glucose metabolism in controlled laboratory conditions.

Streptozotocin-induced models of type 1 diabetes serve as primary experimental systems for evaluating pancreatic islet function and metabolic regulation.

Human umbilical vein endothelial cell (HUVEC) cultures represent the primary in vitro model for investigating the compound’s role in angiogenesis and vascular biology.

Additional research applications include:

Model System	Research Focus	Key Findings
Zucker fatty rats
Diabetic rats
Pulmonary artery banding
High sugar intake models

Molecular Targets and Pathways

Laboratory investigations have shown that the compound decreases hepatic PEPCK (phosphoenolpyruvate carboxykinase) expression, a key enzyme in gluconeogenesis.

The compound’s effects extend to genes associated with mitochondrial function and biogenesis, including:

• MCT1 (monocarboxylate transporter 1): Cellular transport mechanisms
• MFN2 (mitofusin-2): Mitochondrial fusion and biogenesis
• CPT1A: Key enzymes involved in fatty acid oxidation
• CACT: Carnitine transport mechanisms

Experimental Methods and Protocols

Research protocols commonly dissolve GW0742 in DMSO for in vitro studies, achieving concentrations up to 86 mg/mL (182.39 mM at 25°C), or in ethanol at concentrations up to 40 mg/mL (84.84 mM). For in vivo studies, the compound is typically administered using 2% DMSO plus solubilizing agents to ensure uniform exposure and bioavailability.

The specificity of action can be confirmed through co-treatment with the PPARβ/δ antagonist GSK0660, providing important controls for experimental validation.

Standard experimental protocols include:

• Cell Culture Studies: 16-hour incubation periods for tubulogenesis assays
• Animal Studies: Intravenous administration with appropriate vehicle controls
• Molecular Analysis: RT-qPCR and Western blotting for gene and protein expression
• Metabolic Assessment: Hyperinsulinemic-euglycemic clamp procedures
• Vascular Studies: HUVEC tubulogenesis and angiogenesis assays

Research emphasizes the importance of including appropriate vehicle controls (DMSO or ethanol) and following established protocols for reproducible results.

For vivo activation studies, research protocols must account for the compound’s pharmacokinetic properties and ensure proper solubilization for systemic administration. Laboratory guidelines recommend careful attention to handling procedures and storage conditions to maintain compound stability.

Laboratory and Statistical Analysis

Safety and Considerations

Research indicates that the compound’s effects are reversible upon treatment discontinuation, supporting its utility in controlled experimental settings.

Experimental considerations include:

• Concentration Selection: Careful selection to achieve research objectives
• Vehicle Controls: Essential for proper experimental design
• Animal Welfare: Compliance with established guidelines and ethical standards
• Storage Conditions: Appropriate handling to maintain compound integrity
• Experimental Duration: Effects are reversible after discontinuation

Research protocols emphasize the importance of proper experimental design, including appropriate control groups and statistical analysis methods. Studies suggest that the compound’s research applications require careful attention to experimental variables and standardized protocols.

Laboratory safety protocols recommend standard handling procedures for research chemicals, including appropriate personal protective equipment and waste disposal methods. Research facilities must maintain compliance with institutional guidelines for chemical handling and storage.

GW0742 and Vitamin D Receptor (VDR) Interaction

A notable finding in GW0742 research involves its concentration-dependent interaction with the Vitamin D Receptor (VDR). While GW0742 functions as a PPARβ/δ agonist at standard research concentrations, studies have identified that at higher concentrations (above approximately 12.1 μM), the compound exhibits antagonistic activity at both the VDR and Androgen Receptor (AR).

This dual-mode behavior — agonism at lower concentrations and receptor antagonism at higher concentrations — represents a significant research variable.

For preclinical protocol design, this concentration-dependent receptor cross-talk is a critical variable when interpreting GW0742 experimental outcomes, particularly in studies involving vitamin D-dependent biological pathways. Researchers using GW0742 in metabolic or immune models are advised to account for potential VDR interference when assessing receptor selectivity.

Research suggests considerable scientific interest in GW0742 and related peroxisome proliferator activated receptors as targets for understanding metabolic diseases.

Studies indicate promising applications in and obesity research, given the global prevalence of these conditions and the need for better understanding of underlying mechanisms.

Future research directions may include:

• Metabolic Disease Models: Advanced understanding of diabetes and obesity mechanisms
• Cardiovascular Research: Endothelial function and vascular biology studies
• Mitochondrial Research: Energy metabolism and cellular function studies
• Drug Development: Understanding receptor-based therapeutic approaches

Laboratory investigations suggest potential applications in studying free radical biology and cellular protection mechanisms.

GW0742 vs. Cardarine (GW501516): Research Comparison

GW0742 and Cardarine (GW501516) are frequently compared in the research literature due to their shared PPARδ target and overlapping metabolic profiles. However, the compounds differ in several research-critical respects:

Parameter	GW0742	Cardarine (GW501516)
Primary Target	PPARβ/δ (selective agonist)	PPARδ agonist
Original Developer	GlaxoSmithKline	GlaxoSmithKline / Ligand Pharmaceuticals
Human Trial Status	No published Phase I data	Phase II trials conducted (discontinued)
Cardiomegaly Signal	Observed in rodent preclinical models	Not reported
No equivalent data
Primary Research Areas

A key distinguishing factor is the cardiomegaly signal: preclinical research has identified that GW0742 produced measurable cardiac hypertrophy in rodent models at certain concentrations — a safety signal not observed in Cardarine research.

GW0742’s TGF-β elevation data represents a distinct research application not shared by Cardarine.

Conclusion

GW0742 stands as a reference compound for PPARβ/δ research, offering researchers a powerful tool for investigating metabolic pathways, vascular biology, and disease mechanisms. Its robust research profile supports continued use in academic, translational, and pharmaceutical research settings, where it serves as both a probe for understanding nuclear receptor biology and a model for studying metabolic regulation.

Research suggests that this selective agonist will continue to inform our understanding of lipid metabolism, energy homeostasis, and through carefully designed laboratory studies.

For researchers interested in incorporating GW0742 into their studies, adherence to established protocols and ethical guidelines ensures both scientific rigor and responsible research practices. The compound’s continued contribution to metabolic and cardiovascular research depends on maintaining high standards of experimental design and regulatory compliance in research applications.

References

1. Le Garf S, Murdaca J, Mothe-Satney I, et al. Int J Mol Sci. 2019;20(20):5182. doi:10.3390/ijms20205182.
2. Mothe-Satney I, Piquet J, Murdaca J, et al. Biochimie. 2017 May;136:33-41. doi:10.1016/j.biochi.2016.12.001.
3. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008 Aug 8;134(3):405-15. doi:10.1016/j.cell.2008.06.051.
4. Faulkner A, Lynam E, Purcell R, Jones C, Wheeler-Jones C. Context-dependent regulation of endothelial cell metabolism: differential effects of the PPARβ/δ agonist GW0742 and VEGF-A. Sci Rep. 2020;10(1):7849. doi:10.1038/s41598-020-63900-0.
5. Niu HS, Ku PM, Niu CS, Cheng JT, Lee KS. Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals. Drug Des Devel Ther. 2015;9:5625-32. doi:10.2147/DDDT.S95045.
6. Zarzuelo MJ, Jiménez R, Gómez-Guzmán M, et al. Effects of peroxisome proliferator-activated receptor-β activation in endothelin-dependent hypertension. Cardiovasc Res. 2013;99(4):622-31. doi:10.1093/cvr/cvt152.
7. Toral M, Gómez-Guzmán M, Jiménez R, et al. J Hypertens. 2015 Sep;33(9):1831-44. doi:10.1097/HJH.0000000000000634.
8. Abdel-Rahman EA, Bhattacharya S, Buabeid M, et al. J Am Coll Nutr. 2019 Nov-Dec;38(8):693-702. doi:10.1080/07315724.2019.1598307.
9. Cheng KC, Chang WT, Li Y, et al. J Cell Biochem. 2018 Nov;119(11):9532-9542. doi:10.1002/jcb.27270.
10. Faulkner A, Lynam E, Purcell R, et al. Context-dependent regulation of endothelial cell metabolism: differential effects of the PPARβ/δ agonist GW0742 and VEGF-A. Sci Rep. 2020;10:7849. doi:10.1038/s41598-020-63900-0.
11. Chen YC, Tong YC. The effects of PPAR-δ agonist GW0742 on insulin resistance and in diabetic rats. J Diabetes Res. 2015;2015:97125. doi:10.1155/2015/97125.
12. Peters JM, Cheung C, Gonzalez FJ. Pharmacol Rev. 2015;67(2):268-287. doi:10.1124/pr.114.009654.